Filing Flows › Firefly Neuroscience (AIFF) › Q2 2026 › vs Q2 2025
Firefly Neuroscience (AIFF) Q2 2026 vs Q2 2025 (year over year)
Firefly Neuroscience's revenue rose $215K (+72%) from $299K in Q2 2025 to $514K in Q2 2026. The biggest changes: Subscription and Circulation +$243K (—); Service −$59K (-26%); Product +$48K (+109%).
Firefly Neuroscience, Q2 2026: revenue $514K (+72% year over year), operating margin -384.0%, net loss $2.0M, operating cash flow −$1.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Subscription and Circulation | $243K | $0 | $243K | — |
| Service | $164K | $223K | −$59K | -26% |
| Product | $92K | $44K | $48K | +109% |
| Product and Service, Other | $10K | $0 | $10K | — |
| Rentals | $5K | $32K | −$27K | -84% |
| Revenue | $514K | $299K | $215K | +72% |
| Net loss | $2.0M | $1.8M | $151K | +8% |
| Costs & expenses | $2.5M | $2.1M | $366K | +17% |
| Operating costs | $2.5M | $1.9M | $555K | +29% |
| Interest & other, net | $10K | $195K | −$185K | -95% |
| Cost of revenue | $261K | $25K | $236K | +944% |
| Research & development | $525K | $336K | $189K | +56% |
| Sales & marketing | $180K | $199K | −$19K | -10% |
| General & admin | $1.5M | $1.4M | $149K | +11% |
| Operating cash sources | $2.1M | $2.5M | −$445K | -18% |
| Depreciation & amortization | $47K | $43K | $4K | +9% |
| Share-based compensation | $268K | $77K | $191K | +248% |
| Cash used in operations | $1.8M | $2.4M | −$640K | -27% |
| Net loss absorbed | $2.0M | $1.8M | $151K | +8% |
| Working capital & other | $81K | $677K | −$596K | -88% |
Questions
How much did Firefly Neuroscience's revenue grow year over year in Q2 2026?
Firefly Neuroscience's revenue rose $215K (+72%) from $299K in Q2 2025 to $514K in Q2 2026.
What drove Firefly Neuroscience's revenue change in Q2 2026?
Subscription and Circulation +$243K (—); Service −$59K (-26%); Product +$48K (+109%).